TP53mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer-Reference-Cited by-同舟云学术

TP53mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer

Published:2015-08-13 Issue:2 Volume:138 Page:489-496
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Wang Yuxia¹,Xu Ye¹,Chen Jiuan¹,Ouyang Tao¹,Li Jinfeng¹,Wang Tianfeng¹,Fan Zhaoqing¹,Fan Tie¹,Lin Benyao¹,Xie Yuntao¹

Affiliation:

1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education); Breast Center, Peking University Cancer Hospital & Institute; Beijing People's Republic of China

Funder

National Key Technology Research and Development Program of the Ministry of Science and Technology of China

973 Project

National Natural Science Foundation of China

985-III Project

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27;Rastogi;J Clin Oncol,2008

2. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;Mauri;J Natl Cancer Inst,2005